Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 126, Issue 3, 1997, Pages 177-183

  Suissa, Samy ^a   Dennis, Rodolfo ^a   Ernst, Pierre ^a   Sheehy, Odile ^a   Wood Dauphinee, Sharon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY EPITHELIUM; SLEEP DISORDER;

EID: 0031057451     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-3-199702010-00001     Document Type: Article

References (17)

1. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326:862-6.
2. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report Bethesda, MD: National Asthma Education Program, Office of Prevention Education, and Control, National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services, Public Health Service; 1991.
3. International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992. Eur Respir J. 1992;5:601-41.
4. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990;85:1098-111.
5. Rutten-van Molken MP, Van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med. 1992;35:161-75.
6. Rutten-van Molken MP, Van Doorslaer EK, Jansen M, Van Essen-Zandvliel EE, Rutten FF. Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus monotherapy in children with asthma. Pharmacoeconomics. 1993;4:257-70.
7. Rutten-van Molken MP, Van Doorslaer EK, Jansen MC Kerstjens HA, Rutten FF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975-82.
8. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 1995;8:1203-13.
9. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinylleukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337:690-4.
10. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994;150:618-23.
11. ICI Pharma. A multicenter double-blind placebo controlled trial of Accolate in mild to moderate asthmatic patients needing chronic treatment. Trial number 9188IL/0029. Canada, 1992.
12. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness. Pharmacoeconomics. 1993;4:345-52.
13. Armitage P, Berry G. Statistical Methods in Medical Research. Boston: Blackwell Scientific; 1987.
14. McCullagh P, Nelder JA, eds. Generalized Linear Models. 2d ed. London: Chapman & Hall; 1989.
15. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993;119:1059-66.
16. Global strategy for asthma management and prevention. WHO/NHLBI workshop In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication no. 95-3659; 1995.
17. Henry D. Economic analysis as an aid to subsidization decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics. 1992;1:54-67.